TRH attenuates scopolamine-induced memory impairment in humans - PubMed (original) (raw)

Clinical Trial

doi: 10.1007/BF02245795.

Affiliations

Free article

Clinical Trial

TRH attenuates scopolamine-induced memory impairment in humans

S E Molchan et al. Psychopharmacology (Berl). 1990.

Free article

Abstract

The brain tripeptide thyrotropin-releasing hormone (TRH) has been demonstrated to facilitate cholinergic neurotransmission. To test its interaction with the cholinergic system in humans, high-dose TRH (0.5 mg/kg) or placebo was administered intravenously (IV) to normal controls pretreated with scopolamine (0.5-0.75 mg IV), a centrally active muscarinic antagonist, which has been used to model aspects of the memory impairment of normal aging and of dementia. Compared to placebo, TRH markedly attenuated scopolamine-induced impairment of some measures of memory, most notably on a selective reminding task. This cognitive study is the first in humans to suggest a neuromodulatory effect of a peptide on the cholinergic system, and suggests a facilitatory role for TRH in human memory processes.

PubMed Disclaimer

References

    1. Arch Gen Psychiatry. 1987 May;44(5):418-26 -PubMed
    1. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3-5):599-610 -PubMed
    1. Pharmacol Biochem Behav. 1978 Dec;9(6):833-6 -PubMed
    1. Brain Res. 1978 Jul 7;150(1):205-9 -PubMed
    1. Neurology. 1977 Aug;27(8):783-90 -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources